IgA Nephropathy (IgAN) Clinical Trials

18 recruitingLast updated: June 18, 2026

There are 18 actively recruiting iga nephropathy (igan) clinical trials across 9 countries. Studies span Phase 2, Early Phase 1, Not Applicable, Phase 3, Phase 1. Top locations include Beijing, Beijing Municipality, China, Hangzhou, Zhejiang, China, Shanghai, Shanghai Municipality, China. Updated daily from ClinicalTrials.gov.


IgA Nephropathy (IgAN) Trials at a Glance

18 actively recruiting trials for iga nephropathy (igan) are listed on ClinicalTrialsFinder across 6 cities in 9 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in Beijing, Hangzhou, and Shanghai. Lead sponsors running iga nephropathy (igan) studies include Haisco Pharmaceutical Group Co., Ltd., The Children's Hospital of Zhejiang University School of Medicine, and Biocity Biopharmaceutics Co., Ltd..

Browse iga nephropathy (igan) trials by phase

Treatments under study

About IgA Nephropathy (IgAN) Clinical Trials

Looking for clinical trials for IgA Nephropathy (IgAN)? There are currently 18 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new IgA Nephropathy (IgAN) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about IgA Nephropathy (IgAN) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 118 of 18 trials

Recruiting
Phase 2

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

IgA Nephropathy (IgAN)IgANC3G+2 more
ADARx Pharmaceuticals, Inc.45 enrolled29 locationsNCT06989359
Recruiting

RESistance of IgA Nephropathy to Conventional and Newly-approved Therapies: an Observational, Real-life Study (RESIGAN)

IgA Nephropathy (IgAN)
Assistance Publique - Hôpitaux de Paris800 enrolled1 locationNCT06926244
Recruiting
Phase 3

Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN

IgA Nephropathy (IgAN)
Haisco Pharmaceutical Group Co., Ltd.370 enrolled9 locationsNCT07390123
Recruiting
Phase 2

A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy

IgA Nephropathy (IgAN)
Haisco Pharmaceutical Group Co., Ltd.73 enrolled2 locationsNCT07616700
Recruiting
Phase 2

Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases

Focal segmental glomerulosclerosis (FSGS)IgA Nephropathy (IgAN)Minimal Change Disease (MCD)
Everest Medicines (China) Co.,Ltd.45 enrolled2 locationsNCT07614477
Recruiting
Early Phase 1

CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07586267
Recruiting
Early Phase 1

Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07507201
Recruiting
Phase 1

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07305116
Recruiting
Early Phase 1

A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases

IgA Nephropathy (IgAN)Membranous NephropathyANCA-associated Vasculitis (AAV)/ANCA-associated Glomerulonephritis (AAGN)+2 more
Grit Biotechnology30 enrolled1 locationNCT07389499
Recruiting

A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy

IgA Nephropathy (IgAN)Early Initial Therapy
Sichuan Provincial People's Hospital200 enrolled1 locationNCT06676007
Recruiting
Phase 2

A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy

IgA Nephropathy (IgAN)
Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.30 enrolled1 locationNCT07305974
Recruiting
Phase 2

Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)

IgA Nephropathy (IgAN)
Mayo Clinic16 enrolled2 locationsNCT06676579
Recruiting
Not Applicable

Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial

IgA Nephropathy (IgAN)
Botkin Hospital30 enrolled1 locationNCT07056595
Recruiting
Phase 2

Monthly Dosing of Atacicept in IgAN

IgA Nephropathy (IgAN)Berger Disease
Vera Therapeutics, Inc.90 enrolled1 locationNCT07020923
Recruiting
Phase 3

A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria

IgA Nephropathy (IgAN)
Biocity Biopharmaceutics Co., Ltd.360 enrolled1 locationNCT06819826
Recruiting

Raman Spectroscopy Diagnosis of Kidney Diseases

Focal segmental glomerulosclerosis (FSGS)IgA Nephropathy (IgAN)Membranous Nephropathy+1 more
Zunsong Wang200 enrolled1 locationNCT06760845
Recruiting
Not Applicable

Efficacy and Safety of Telitacicept in IgAN

GlucocorticoidKidney DiseasesIgA Nephropathy (IgAN)+1 more
Ruijin Hospital118 enrolled1 locationNCT06654596
Recruiting
Phase 2

Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients with Primary IgAN

IgA Nephropathy (IgAN)
Haisco Pharmaceutical Group Co., Ltd.80 enrolled2 locationsNCT06670352